September 28, 2023 Oculus, Inc. has announced a strategic partnership with LUVO to bring new specialty care devices to the U.S. optometry and ophthalmology market. This partnership serves to equip eye care practitioners with the
September 14, 2023 VAUGHAN, Ontario — Bausch + Lomb Corporation has announced the U.S. commercial launch of Miebo (perfluorohexyloctane ophthalmic solution) for the treatment of the signs and symptoms of dry eye disease (DED). Miebo is the
August 8, 2023 TOKYO — Astellas Pharma Inc. announced the U.S. Food and Drug Administration (FDA) approved Izervay (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
August 1, 2023 CHESTERFIELD, Mo. — EyePromise has announced the latest addition to its comprehensive nutritional system for eye care practices. The new Zx Pro offers the latest in biomarker technology and allows eye care
July 25, 2023 IRVINE, Calif. — Tarsus Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) approved XDEMVY (lotilaner ophthalmic solution) 0.25% for the treatment of demodex blepharitis. XDEMVY, formerly known as TP-03,
July 18, 2023 NASHVILLE, Tenn. — Harrow Health, Inc. has announced agreements with affiliates of Santen Pharmaceutical Co., Ltd., under which Harrow will acquire certain U.S. and Canadian commercial rights for the following branded
July 19, 2023 LIÈGE, Belgium – BVI Medical Inc. has opened a new facility here to increase its intraocular lens (IOL) production capacity. This results in a sizeable increase in BVI’s IOL production capacity, unlocking
July 18, 2023 NASHVILLE, Tenn. and HEIDELBERG, Germany — Harrow and Novaliq GmbH announced an agreement under which Harrow will acquire the U.S. and Canadian commercial rights for VEVYE (cyclosporine ophthalmic solution) 0.1%, a patented,
July 11, 2023 NEW YORK—The adoption of telemedicine has shown an increase in eye care, particularly during the COVID-19 pandemic. Jobson Research’s recent Telemedicine Research report focuses on the integration of telemedicine into contact lens care,
July 6, 2023 BRIDGEWATER, N.J. – RVL Pharmaceuticals has launched ELEVATE, a first-of-its-kind, proprietary prescription e-commerce platform. This platform aligns with RVL’s vision of seamlessly integrating its products into customers’ practices while further enhancing patient
July 6, 2023 VAUGHAN, Ontario — With the recent announcements of acquisitions of XIIDRA and Blink following the FDA approval of Miebo, Bausch + Lomb Corp. has substantially and quickly expanded its dry eye offerings.
June 5, 2023 VAUGHAN, Ontario — Bausch + Lomb Corporation announced the U.S. launch of Bausch + Lomb INFUSE Multifocal silicone hydrogel (SiHy) daily disposable contact lenses. Featuring a next-generation material infused with ProBalance Technology
June 6, 2023 VAUGHAN, Ontario — Bausch + Lomb Corporation has announced the U.S. launch of Biotrue Hydration Boost Contact Lens Rehydrating drops, the first and only preservative-free rehydrating drop in a multi-dose bottle that is indicated to
June 13, 2023 VAUGHAN, Ontario —Bausch + Lomb Corporation has announced the U.S. launch of PreserVision AREDS 2 Formula soft gels plus coenzyme Q10 (CoQ10). Developed as a convenient two-in-one option, PreserVision AREDS 2 Formula eye vitamins plus
June 8, 2023 HEIDELBERG, Germany and CAMBRIDGE, Mass.— Novaliq GmbH, has announced that the U.S. Food and Drug Administration (FDA) has approved VEVYE (cyclosporine ophthalmic solution) 0.1% for the treatment of the signs and symptoms of
May 18, 2023 VAUGHAN, Ontario, and HEIDELBERG, Germany — Bausch + Lomb Corporation and Novaliq GmbH announced that the U.S. Food and Drug Administration (FDA) has approved Miebo, (perfluorohexyloctane ophthalmic solution) formerly known as NOV03,
May 5, 2023 Aliso Viejo, Calif. – Glaukos Corporation announced it has received the “Day 74” notification from the U.S. Food and Drug Administration acknowledging the previously submitted New Drug Application (NDA) for iDose TR (travoprost intraocular
May 5, 2023 SEATTLE – Visus Therapeutics Inc., has presented key topline data from the pivotal Phase 3 BRIO-I clinical trial. The study evaluating the safety and efficacy of BRIMOCHOL PF, a preservative-free ophthalmic solution
JENA, Germany, and DUBLIN, Calif. – The U.S. Food and Drug Administration (FDA) has approved the CT LUCIA 621P Monofocal IOL from ZEISS Medical Technology. The aspheric, monofocal, single-piece C-loop IOL features the patented ZEISS Optic Asphericity
DALLAS – Celanese Corporation, a global specialty materials and chemical company, has entered into an agreement with Glaukos Corporation to supply its VitalDose Drug Delivery Platform for use as a component in Glaukos’ iDose TR,
BIRMINGHAM, Mich. – MacuHealth has introduced LifeMeter, a portable, non-invasive device that measures the presence of carotenoids in patients. Carotenoids in the macular pigment protect the retina from damage caused by blue light and oxidative
FREMONT, Calif. — The U.S. Food and Drug Administration has granted 510(k) clearance to Nova Eye Medical Limited’s new canaloplasty device, iTrack Advance. The newest generation canaloplasty device for canal-based glaucoma surgery will be available
WALTHAM, Mass. — The U.S. Food and Drug Administration has approved SYFOVRE (pegcetacoplan injection) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). From global biopharmaceutical company Apellis Pharmaceuticals, Inc., SYFOVRE
NORTH CHICAGO, Ill. – AbbVie, the parent company of Allergan, has announced that the FDA has approved a twice-daily dosing option of Vuity (pilocarpine HCl ophthalmic solution) 1.25% in adults with presbyopia. Vuity is the
